Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?

Date publication

novembre 2014

Journal

World journal of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ORRY David

Tous les auteurs :
Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25407113

Résumé

The purpose of this study is to report prolonged survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) managed by chemotherapy and surgery.

Mots clés

Adenocarcinoma, drug therapy, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Pancreatic Ductal, drug therapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Liver Neoplasms, drug therapy, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, drug therapy, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms, drug therapy, Peritoneal Neoplasms, drug therapy, Prognosis, Retrospective Studies, Survival Rate

Référence

World J Surg Oncol. 2014 Nov 18;12:347